The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Pembrolizumab FDA approval for the treatment of R/R PMBCL
On 13 June 2018, the US Food and Drug Administration (FDA) granted approval of pembrolizumab (KEYTRUDA) for the treatment of adult and pediatric patients with relapsed or refractory (R/R) primary mediastinal large B-cell lymphoma (PMBCL).
Pembrolizumab is an anti-PD-1 drug and represents the first anti-PD-1 therapy to be approved for the treatment of PMBCL. The FDA approval was based on the results from the open-label, multi-center, single-arm KEYNOTE-170 study (NCT02576990) in which 53 patients with PMBCL were treated with pembrolizumab. The overall response rate was 45% (95% CI, 32, 60) with 11% of patients achieving a complete response at a median follow-up of 9.7 months.